Daily Cosmetic Research Analysis
Three advances span the cosmetic sciences: a randomized, placebo-controlled trial shows perioperative skincare reduces laser/IPL-induced barrier damage and erythema; a high-loading cavity microneedle system boosts intradermal delivery of niacinamide; and a de novo biosynthetic route enables sustainable microbial production of D-panthenol from glucose via a rationally redesigned enzyme.
Summary
Three advances span the cosmetic sciences: a randomized, placebo-controlled trial shows perioperative skincare reduces laser/IPL-induced barrier damage and erythema; a high-loading cavity microneedle system boosts intradermal delivery of niacinamide; and a de novo biosynthetic route enables sustainable microbial production of D-panthenol from glucose via a rationally redesigned enzyme.
Research Themes
- Perioperative skincare to preserve skin barrier after energy-based cosmetic procedures
- Intradermal delivery innovations for cosmetic actives
- Sustainable biomanufacturing of cosmetic ingredients
Selected Articles
1. De novo biosynthesis of D-panthenol in engineered E. coli with rationally designed L-homoserine decarboxylase.
The authors engineered a novel biosynthetic pathway to produce D-panthenol directly from glucose by designing a tyrosine decarboxylase mutant that decarboxylates L-homoserine to 3-amino-1-propanol, and by identifying a pantothenate synthetase enabling efficient condensation to D-panthenol. Functional expression in E. coli achieved de novo production, offering a potentially cleaner, sustainable manufacturing route for a key cosmetic active.
Impact: This is a first demonstration of an unnatural enzymatic step enabling full de novo microbial production of D-panthenol, with implications for greener, stereoselective manufacturing of a widely used cosmetic ingredient.
Clinical Implications: While not directly clinical, sustainable bioproduction could reduce impurities and costs in D-panthenol supply, potentially improving product quality and accessibility in dermatologic formulations.
Key Findings
- Rational design of a tyrosine decarboxylase mutant enabled a previously unreported decarboxylation of L-homoserine to 3-amino-1-propanol.
- Screening identified a D-pantothenate synthetase that efficiently condenses 3-amino-1-propanol with D-pantoate to form D-panthenol.
- The artificial pathway was functionally expressed in minimally engineered E. coli, achieving de novo D-panthenol production from glucose.
Methodological Strengths
- Structure-guided enzyme redesign with mechanistic rationale
- Systematic enzyme screening to complete a functional multi-step pathway in vivo
Limitations
- Titers, yields, and process economics are not quantified in the abstract
- No scale-up data or downstream purification assessment reported
Future Directions: Optimize strain and pathway flux for higher titers, assess enantiopurity and impurities, and evaluate scalability and life-cycle impacts compared with chemical synthesis.
D-panthenol is a compound of significant importance in the pharmaceutical, cosmetic, and nutraceutical sectors, attributed to its remarkable moisturizing, anti-inflammatory, and tissue repair properties. Traditional chemical synthesis encounters several challenges, including the generation of toxic by-products, low enantiomeric excess, and expensive purification processes. To date, complete biosynthesis of D-panthenol solely from glucose has seldom been documented. In this study, we have developed a new fermentative route to produce D-panthenol. The pathway incorporates previously unreported reaction of decarboxylating L-homoserine to 3-amino-1-propanol, which is achieved by rational design of a novel tyrosine decarboxylase mutant, informed by structural and mechanistic insights into enzymes acting on sterically similar substrates. The next enzyme facilitating the condensation of 3-amino-1-propanol with D-pantoate for D-panthenol formation was identified through a comprehensive screening of natural D-pantothenate synthetases. The artificial pathway was functionally expressed in a minimally engineered E. coli strain, resulting in the de novo production of D-panthenol from glucose. This research highlights a demonstration of an unnatural enzymatic synthesis process for D-panthenol. With further strain and process engineering, this new approach could be a promising way to produce D-panthenol biologically.
2. PowderInjector microneedles: smart cavity microneedles as a novel intradermal delivery system for high doses of niacinamide.
A powder-laden cavity microneedle (PowderInjector) design achieved approximately threefold higher niacinamide loading (∼2060 µg) than standard dissolving microneedles, maintained crystallinity, and improved insertion efficiency. The concentrated-shell, powder-core design (D3) delivered higher intradermal flux, demonstrating a promising strategy to bypass stratum corneum limitations for hydrophilic cosmetic actives.
Impact: Introduces a novel microneedle architecture that substantially increases dose capacity and delivery of a widely used cosmetic active, addressing a key limitation of dissolving microneedles.
Clinical Implications: If safety and usability are confirmed in humans, this platform could enable efficacious intradermal dosing of niacinamide for conditions like dyschromia, barrier dysfunction, or inflammation with minimal downtime.
Key Findings
- Cavity microneedles formed well-defined powder cores up to 0.6 mm (~50% of needle length).
- D3 (concentrated shell + powder core) increased niacinamide loading ~3-fold versus standard dissolving microneedles (∼2060 µg vs 711 µg).
- Cavity designs preserved niacinamide crystallinity and enhanced insertion efficiency.
- Intradermal flux of niacinamide was higher with D3 than with conventional designs.
Methodological Strengths
- Head-to-head comparison of three microneedle architectures with standardized mechanical and delivery assays
- Quantitative loading and intradermal flux assessment
Limitations
- Preclinical evaluation without human clinical testing
- Long-term skin tolerability, stability, and dose uniformity not yet characterized
Future Directions: Conduct human safety and pharmacodynamic studies, assess repeat-application tolerability, and expand to other hydrophilic actives for aesthetic dermatology.
Niacinamide (NIA) is widely used in cosmetic formulations due to its anti-inflammatory and antioxidant properties. However, its hydrophilic nature (log p = - 0.35) limits penetration through the stratum corneum (SC), necessitating advanced delivery systems. While formulation-enhancement technologies (penetration enhancers, liposomes) still face the SC diffusion barrier, dissolving microneedles (DMNs) bypass the SC. As micron-scale needles made from biocompatible polymers in which the cargo is incorporated, DMNs can limit cargo loading capacity and can compromise stability. Therefore, the aim of this study was to develop novel high-loading ''PowderInjector'' DMNs (powder-laden, cavity DMNs). Hence, traditional DMNs with NIA in the polymeric matrix (D1) were compared to cavity DMNs containing NIA in powder form only (D2) and cavity DMNs with a concentrated NIA shell and powder-filled cavity (D3). The DMNs were evaluated for mechanical properties, insertion efficiency, dissolution time, loading capacity and intradermal delivery. The cavity DMNs demonstrated well-defined powder cores up to 0.6 mm (approximately 50 %) of the needle length. NIA content was 3-fold higher in D3 (∼2060 ± 288 µg) compared to D1 (711 ± 286 µg), with better preservation of NIA crystallinity. All DMNs had sufficient structural integrity for insertion with enhanced efficiency in the cavity DMNs. NIA flux rates within the skin were higher in D3 (272.14 ± 48.20 μg/cm
3. Efficacy and safety of commercially available cosmetic perioperative skincare products for non-invasive energy-based device treatment: a single-centre, randomized, placebo-controlled trial.
In a single-centre randomized, placebo-controlled trial with a four-week timeline, perioperative use of a soothing gel alone or combined with a repair serum reduced TEWL and increased stratum corneum hydration 24 hours post-treatment versus placebo. Redness decreased more on the picosecond laser side across all timepoints, and co-use better alleviated sensitivity symptoms, with both products well tolerated.
Impact: Provides randomized clinical evidence supporting perioperative skincare to mitigate barrier damage and erythema after picosecond laser/IPL, informing practical protocols in cosmetic dermatology.
Clinical Implications: Clinicians may consider structured perioperative barrier-support regimens to reduce downtime and adverse cutaneous reactions after energy-based treatments, while recognizing brand-agnostic principles (TEWL reduction and hydration support).
Key Findings
- Both gel alone and gel+serum groups showed greater TEWL reduction and increased stratum corneum hydration at 24 hours versus placebo.
- Redness decreased more on the picosecond laser-treated side at all follow-up timepoints versus placebo.
- The co-use regimen better alleviated skin sensitivity symptoms; both regimens were well tolerated with favorable safety.
Methodological Strengths
- Randomized, placebo-controlled design with objective non-invasive measurements (TEWL, hydration)
- Multi-modal assessment including self-report and clinical evaluation
Limitations
- Single-centre trial with short follow-up; sample size not reported in abstract
- Potential lack of blinding details and no long-term outcomes
Future Directions: Replicate in larger, multicentre, blinded RCTs with longer follow-up, include diverse skin types, and compare different barrier-support formulations head-to-head.
Photoelectric therapies (or non-invasive energy-based device treatment), especially picosecond lasers and intense pulsed light (IPL) treatments, are widely used to manage various cutaneous conditions, including pigmentation, inflammation, and signs of aging. However, these treatments can also impair the integrity of the skin barrier, making post-treatment repair of skin barrier function essential to maintain perioperative curative effects. To evaluate the safety and efficacy of Eucerin® UltraSensitive Soothing Care Gel (GEL) and co-use of GEL and Eucerin® UltraSensitive Repair Intensive Source Serum (CO-USE) during the perioperative procedure. This study was designed with a four-week follow-up period, in which the first two weeks represented a pre-treatment phase. Self-assessment, clinical evaluation, and non-invasive skin testing were used at each visit after treatments to determine the efficacy of the two products. Compared to the placebo (PBO) group, both the GEL and CO-USE groups exhibited a significantly greater reduction in transepidermal water loss (TEWL) and a notable increase in stratum corneum hydration (SCH) 24 hours post treatment. Regarding facial redness, there was a significantly greater decrease in the GEL and CO-USE groups compared to the PBO group at all follow-up time points on the picosecond laser side. Moreover, the CO-USE group showed superior efficacy in alleviating skin sensitivity symptoms following the interventions. Both products were well tolerated and exhibited favourable safety profiles. Both commercially available skincare products tested in the present study were found to be clinically effective in inhibiting laser-induced skin barrier damage, and reducing skin redness and skin sensitivity.